EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Improved Detection of Minimal Residual Disease in AML: Validation of IDH1/2 ddPCR Assays in the Perspective of Treatment with Target Inhibitors

Katsiaryna Nikitsenka iD, Giacomo Danieli iD, Lucia Tombolan, Barbara Mancini iD, Davide Facchinelli iD, Giorgia Scotton, Alberto Tosetto iD, Omar Perbellini iD, Daniela Zuccarello iD, Elisabetta Novella iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262110397 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Katsiaryna Nikitsenka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Genetics and Genomic Unit, San Bortolo Hospital, 36100 Vicenza, Italy. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Neoplasm, Residual, Leukemia, Myeloid, Acute, Polymerase Chain Reaction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in IDH1/2 are frequent in Acute Myeloid Leukemia (AML), defining a molecularly distinct subgroup with therapeutic implications due to the availability of specific inhibitors. Accurate monitoring of treatment response is crucial and Droplet Digital PCR (ddPCR) offers a sensitive approach for quantifying mutational burden in IDH-mutated AML. This study aimed to optimize and validate ddPCR assays specific for IDH1 R132 and IDH2 R172/R140 mutations for future use in Minimal Residual Disease (MRD) monitoring. Four ddPCR assays were set to evaluate the trend of IDH1/2 mutations in 191 diagnostic and follow-up samples. Each validation procedure included determining the limit of blank (LOB) and limit of detection (LOD) using titration series. Moreover, in AML harboring both IDH and NPM1 mutations, we performed generalized estimating equations (GEE) to assess the association between IDH fractional abundance and NPM1 RQ-Ratio across time points. Four IDH1/2 ddPCR assays were validated, demonstrating high sensitivity with limits of detection of 0.07% for IDH1 R132H, 0.1% for IDH2 R140Q and R172K, and 0.2% for IDH1 R132C. The method also exhibited excellent intra-run reproducibility, providing consistent results for patient follow-up. Comparison of IDH and NPM1 trends during follow-up revealed a statistically significant positive correlation, both in raw (β = 0.079, p = 0.001) and ranked data (β = 0.99, p = 0.004), suggesting a co-dynamic pattern potentially useful for surrogate monitoring. While our study cannot yet define the clinical role of IDH mutation assessment by ddPCR due to the lack of comparative follow-up studies, it establishes a solid methodological foundation for standardizing minimal residual disease evaluation via ddPCR, paving the way for future prospective validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseNeoplasm, ResidualLeukemia, Myeloid, AcutePolymerase Chain ReactionHumansNucleophosminMutationFemaleMaleMiddle AgedAdultAged

Stichwörter der Autor:innen

AML molecular markersIDH geneIDH1 R132CIDH1 R132HIDH2 R140QIDH2 R172KLOBLODMRDddPCR

Substanzen

Isocitrate DehydrogenaseNucleophosminIDH2 protein, humanIDH1 protein, humanNPM1 protein, human

Autor:innen und Institutionen

  • Medical Genetics and Genomic Unit, San Bortolo Hospital, 36100 Vicenza, Italy.
  • Hematology Unit, San Bortolo Hospital, 36100 Vicenza, Italy.
  • Public Health and Prevention Department, San Bortolo Hospital, 36100 Vicenza, Italy.

ORCID-Profile: Katsiaryna Nikitsenka, Giacomo Danieli, Barbara Mancini, Davide Facchinelli, Alberto Tosetto, Omar Perbellini, Daniela Zuccarello, Elisabetta Novella

Zitieren

APA

Nikitsenka, K., Danieli, G., Tombolan, L., Mancini, B., Facchinelli, D., Scotton, G., Tosetto, A., Perbellini, O., Zuccarello, D., & Novella, E. (2025). Improved Detection of Minimal Residual Disease in AML: Validation of IDH1/2 ddPCR Assays in the Perspective of Treatment with Target Inhibitors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110397

Vancouver

Nikitsenka K, Danieli G, Tombolan L, Mancini B, Facchinelli D, Scotton G, et al. Improved Detection of Minimal Residual Disease in AML: Validation of IDH1/2 ddPCR Assays in the Perspective of Treatment with Target Inhibitors. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110397

BibTeX
@article{Nikitsenka2025,
  author = {Nikitsenka, Katsiaryna and Danieli, Giacomo and Tombolan, Lucia and Mancini, Barbara and Facchinelli, Davide and Scotton, Giorgia and Tosetto, Alberto and Perbellini, Omar and Zuccarello, Daniela and Novella, Elisabetta},
  title = {Improved Detection of Minimal Residual Disease in AML: Validation of IDH1/2 ddPCR Assays in the Perspective of Treatment with Target Inhibitors},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262110397}
}
Kostenlos starten →